- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05199506
Study to Evaluate the Safety and Effectiveness of the RAP Device for the Improvement in the Appearance of Cellulite
A Single Center Prospective Study to Evaluate the Safety and Effectiveness of the Soliton® Rapid Acoustic Pulse (RAP)™Device for the Improvement in the Appearance of Cellulite.
Study Overview
Detailed Description
This is a non-significant risk, single-center, prospective trial for safety, and efficacy using Soliton's RAP device for the improvement in the appearance of cellulite performed at 1 (one) clinical research site in the United States.
Approximately 15 healthy female participants between the age of 18-55 inclusive will be enrolled in this study.
Participants who sign the informed consent form and meet all the eligible criteria will be enrolled in the study. Each participant will undergo acoustic rapid pulse (RAP) treatments on each of the participants buttocks and legs. The participant's right buttock and leg will receive 100 Hz doses, and the participants left buttock and leg will receive 50 Hz doses.
Total study duration is anticipated to be at or less than 55 weeks from the first participant visit to the last participant observation visit. A total of 3 visits, plus two optional visits are planned for this study as listed below:
- Visit 1: Baseline/Screening (-30 Days to Day 0)
- Visit 2: Treatment (Day 0)
- Visit 3: 12-week Follow-Up Visit (+/- 14 Days)
- Visit 4: 26-week Follow-Up Visit (+/- 14 Days) (Optional)
- Visit 5: 52 Week Follow-Up Visit (+/- 14 Days) (Optional)
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- The Practice of Brian Biesman
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Seeking treatment of cellulite in the thigh and/or buttock areas
- Area of moderate to severe cellulite on thigh and/or buttock for both legs using the Cellulite Dimple - At Rest Scale at Baseline with grades of 2 or 3 based on review of photos taken under the same lightening conditions planned for the trial.
- Body Mass Index (B.M.I.) is ≤ 30
- Participant will not have had invasive or energy-based cellulite treatments (liposuction, subcision, RF, laser, ESWT, etc.) for the prior 12 months.
- Participant will not have used topical based cellulite treatments for prior 6 months and will not use during the trial.
- Participant will not have used spray-on tanning treatments for 6 months prior to the initiation of the trial. Furthermore, participants will not use spray-on tanning treatments during the term of the trial.
- Participants must be able to provide written informed consent, understand and is willing to comply with all study related procedures and follow-up visits.
Exclusion Criteria:
- Participant is unwilling to have research photos taken of treatment areas in the presence of Sponsor's researchers.
- Participant is unwilling to have RAP treatment provided in the presence of Sponsor's researchers.
- Participant is pregnant or planning to become pregnant during the duration of the study.
- Participant is unwilling to commit to follow-up visits
- Metal or plastic implants in the area of the treatment (vascular stent, or implants in the hips, knees, etc.).
- Active electronic implants such as pacemakers, defibrillators.
- History of coagulopathy(ies) and/or on anticoagulant medication.
- Skin disorders (skin infections or rashes, extensive scarring, psoriasis, etc.) in the treatment area.
- Any surgical procedure in the treatment areas in the prior 3 months or planned during the duration of the study.
- Participant is a current smoker.
- Participant has tattoo in treatment area.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Each leg/buttock will be treated with the RAP device
Each leg will be treated with standard RAP treatment settings.One leg will receive treatments with 100Hz and the other with 50hz
|
Treatment of cellulite with RAP device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessing safety
Time Frame: Immediately post treatment
|
The primary safety short-term endpoint to be met if all treated participants were free from unexpected adverse events (UAEs) or serious adverse events (SAEs) attributable to the RAP treatment immediately post-treatment
|
Immediately post treatment
|
Assessing safety
Time Frame: 12 weeks post treatment
|
The primary safety short-term endpoint to be met if all treated participants were free from unexpected adverse events (UAEs) or serious adverse events (SAEs) attributable to the RAP treatment at the short-term (12-week) visit.
|
12 weeks post treatment
|
Assessing Efficacy
Time Frame: At 12 week follow up visit
|
The primary effectiveness objective was to demonstrate improvement in the appearance of cellulite from the 100 Hz treatment is comparable to the 50 Hz treatment.
Efficacy determined by the results of a blinded independent physician assessment (IPA) panel correctly identifying the 12-week post-treatment photographs from randomly placed side-by-side comparison of before and after photographs for both treatments.
The primary effectiveness endpoint will be met if the rate of correctly identified before and after photos for 100 Hz treatment is not significantly lower than the 50 Hz treatment assessment.
|
At 12 week follow up visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessing Participant Satisfaction
Time Frame: At the 12 week follow up visit
|
Improvement in cellulite as measured by the percentage of participants who agree or strongly agree that the final photograph of the treatment area as compared to the baseline photograph, appears improved.
|
At the 12 week follow up visit
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Chris Capelli, MD, Sponsor GmbH
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cellulite
-
Endo PharmaceuticalsCompletedEdematous Fibrosclerotic Panniculopathy (Cellulite)United States
-
Galderma R&DCompletedCellulite of the ButtocksBrazil
-
DSM Nutritional Products, Inc.TerminatedCellulite (Orange Peel Skin)Brazil
-
Nutrasource Pharmaceutical and Nutraceutical Services...Completed
-
InMode MD Ltd.Completed
-
Syneron MedicalTerminatedCircumference Reduction | Cellulite ReductionUnited States
-
Cairo UniversityNot yet recruitingEfficacy of Treatment of Cellulite Using Carboxy Therapy
-
Cutera Inc.CompletedTreatment for Cellulite on the Stomach and FlanksUnited States
-
Endo PharmaceuticalsCompletedEdematous Fibrosclerotic Panniculopathy (Cellulite)United States
-
Caliway Biopharmaceuticals Co., Ltd.Completed
Clinical Trials on RAP
-
SolitonCompletedCelluliteUnited States
-
AZ Sint-Jan AVRecruitingAortic Valve StenosisBelgium
-
Population Health Research InstituteNot yet recruitingRed Blood Cell Transfusion
-
Zeltiq AestheticsRecruiting
-
Rapport Therapeutics Inc.Not yet recruiting
-
Zeltiq AestheticsActive, not recruiting
-
SolitonCompletedCelluliteUnited States
-
Johns Hopkins Bloomberg School of Public HealthEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedDepressive Symptoms | Trauma, Psychological | Disruptive BehaviorUnited States
-
Minia UniversityCompletedGERD | Obesity, MorbidEgypt
-
SolitonUnited States Naval Medical Center, San DiegoNot yet recruitingScars, Hypertrophic